Developmental processes underlying normal tissue regeneration have been implicated in
cancer, but the degree of their enactment during tumor progression and under the selective …

To identify therapeutic targets in acute myeloid leukemia (AML), we chemically interrogated
200 sequenced primary specimens. Mubritinib, a known ERBB2 inhibitor, elicited strong anti-…

Acute myeloid leukemia (AML) is a genetically heterogeneous hematologic malignancy,
which is initiated and driven by a rare fraction of leukemia stem cells (LSCs). Despite the …

Using next-generation sequencing of primary acute myeloid leukemia (AML) specimens, we
identified to our knowledge the first unifying genetic network common to the two subgroups …

Dendritic cells (DCs) play a critical role in orchestrating adaptive immune responses due to
their unique ability to initiate T cell responses and direct their differentiation into effector …

Based on transcriptomic analyses of thousands of samples from The Cancer Genome Atlas,
we report that expression of constitutive proteasome (CP) genes (PSMB5, PSMB6, PSMB7) …

RUNX1 is mutated in ∼10% of adult acute myeloid leukemia (AML). Although most RUNX1
mutations in this disease are believed to be acquired, they can also be germline. Indeed, …

Acute myeloid leukemias (AML) are characterized by mutations of tumor suppressor and
oncogenes, involving distinct genes in adults and children. While certain mutations have been …

In this study, we analyzed RNA-sequencing data of 14 samples characterized by biallelic
CEBPA (CEBPA bi ) mutations included in the Leucegene collection of 415 primary acute …

Acute myeloid leukemias (AML) with mutations in the NPM1 gene (NPM1c+) represent a
large AML subgroup with varying response to conventional treatment, highlighting the need to …